Amylin receptor activation in the area postrema and lateral parabrachial nucleus reduces the rewarding value of food, decreases meal size, and promotes earlier satiation
aleniglipron is planning Phase 3 GI tolerability : Aleniglipron has higher nausea rates (65% vs lower for orforglipron) Dose exploration : Aleniglipron explored higher doses (240 mg) with greater efficacy Maintenance data : Orforglipron has ATTAIN-MAINTAIN validation
Many people find that they still feel hungry because their brain is looking for the dopamine hit that food provides, rather than actual nourishment
Phase 2 cagrilintide weight-management trial Review of cagrilintide and related safety data ClinicalTrials.gov cagrilintide study listings Cagrilintide side effects are best understood as a pattern: digestive symptoms are common, while dehydration, allergic symptoms, severe abdominal pain, or glucose problems need timely review
DPP-4 inhibitors as potential candidates for antihypertensive therapy: Improving vascular inflammation and assisting the action of traditional antihypertensive drugs